Labcorp Holdings Inc. (NYSE: LH) has announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. Dr. Sampson, a nationally recognized neurosurgeon, physician-scientist, and academic leader, brings extensive experience spanning clinical care, biomedical research, medical education, and large-scale health system leadership. As a practicing neurosurgeon and member of the National Academy of Medicine, he has authored nearly 300 peer-reviewed publications and has a long track record of research focused on advancing new therapies for neurologic disease.
Dr. Sampson's appointment to the Board of Directors has led to his appointment to the Quality and Compliance Committee, reflecting Labcorp's commitment to upholding high standards in quality and compliance.
Labcorp, with nearly 70,000 employees serving clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA and performs more than 700 million tests annually for patients around the world.
The company's CEO, Adam Schechter, has expressed confidence that Dr. Sampson's expertise will help advance Labcorp’s strategy across diagnostics and drug development and enhance the value delivered to customers. Dr. Sampson's deep expertise in oncology, neuroscience, women’s health, and personalized medicine aligns with Labcorp’s strategic areas of focus, positioning the company to further its mission of improving health and improving lives. Today the company's shares have moved 0.74% to a price of $270.87. For more information, read the company's full 8-K submission here.
